Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy

Johnson & Johnson (NYSE:JNJ) is one of the best dividend aristocrat stocks to buy now.

On June 17, Johnson & Johnson (NYSE:JNJ) chief executive officer announced that the company doesn’t intend to enter the obesity drug market. Instead, all the focus is on cancer and neuroscience, seen as viable areas for long-term growth. In addition, the company is focused on becoming the top cancer company by 2030 as it currently leads in the treatment of multiple Myeloma.

Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy

Gil C/Shutterstock.com

Last year, Johnson & Johnson spent $3.05 billion to acquire Halda Therapeutics as it sought to gain access to a key oral therapy for prostate cancer. In addition, the company has identified dementia as a major healthcare challenge that it intends to tackle amid heightened investments in neurodegenerative diseases.

Johnson & Johnson has also ramped up investments and focused on artificial intelligence, a technology it believes will help speed up drug discovery.

Johnson & Johnson (NYSE:JNJ) is a global healthcare company that develops pharmaceuticals, medical devices, and consumer health products. They focus on medical innovation to fight complex diseases while also producing everyday health and personal care goods used by millions worldwide.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 UK Stocks with the Highest Dividends and 10 Best Falling Stocks to Invest In According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1